John Lippincott, MD
Ophthalmology · Portland, MENPI 1871094110
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.7%), speaking fees and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Alimera Sciences, Inc. at 35.2% of the total. Reporting peaked in 2023 at $418 and has fallen 87.5% since, to $52 in 2025.
Across 13 payments — averaging $76.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$350
- Dutch Ophthalmic, USA$143
- AbbVie$126
- Alcon$114
- Bausch & Lomb, A Division Of Bausch Health US, LLC$99
- Regeneron$68
- plus $93 from 3 others
What the payments were for
- Speaking & faculty fees$35035%
- Food & beverage$54455%
- Education$10010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 1 | $350 |
| Dutch Ophthalmic, USA | 2 | $143 |
| AbbVie(2 entities) | 2 | $126 |
| Alcon | 1 | $114 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $99 |
| Regeneron | 1 | $68 |
| Genentech USA, Inc. | 3 | $52 |
| Glaukos Corporation | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$350
- AcrySof IQ VIVITY IOL$114
How this compares
$994 in reported general payments places this provider in the 70th percentile of 74 ophthalmology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 51 | $2,980 |
| Ofloxacin | 33 | $409 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 17 | $201 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Portland
- Charles ZacksPortland$36K
- Hallie HahnPortland$5K
- Samuel SolishPortland$4K
- Ravindra ShahPortland$4K
- Richard FrancePortland$4K
- Tamzid RahmanPortland$3K
- Margaret PollardPortland$1K
- Jackie NguyenPortland$1K
- Adam SisePortland$1K
- Benjamin FowlerPortland$763
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.